Table 2 |
||||
|
Incidence of Drug-related Adverse Event by COSTART terma |
||||
|
Blinded Period |
Open-Label Period |
Follow-Up Period |
||
|
Fenoldopam |
Fenoldopam |
|
||
|
0.05 |
3.2 |
Fenoldopam |
Fenoldopam[PR2] |
|
|
Adverse |
mcg/kg/min |
mcg/kg/min |
[PR1](N = 74) |
(N = 77[PR3]) |
|
Events |
(N = 15) |
(N = 15) |
||
|
|
||||
|
OVERALL |
1 (7%) |
3 (20%) |
13 (17%) |
1 (1%) |
|
Hypotension |
1 (7%) |
3 (20%) |
9 (12%) |
0 |
|
Tachycardia |
0 |
0 |
2 (3%) |
0 |
|
Bradycardia |
0 |
0 |
1 (1%) |
0 |
|
Hemorrhage |
0 |
0 |
1 (1%) |
0 |
|
Hypokalemia |
0 |
0 |
1 (1%) |
0 |
|
Oliguria |
0 |
0 |
0 |
1 (1%) |
|
|
||||
|
a Adverse events considered by the investigator to be possibly or probably related to study drug. |
||||
|
Hammer et al. BMC Anesthesiology 2008 8:6 doi:10.1186/1471-2253-8-6 |
||||
